TB-500 (Thymosin Beta-4) 2mg (price is per vial)

$33.92 If paid in BTC $27.13

In stock

Click To Check Quantity Discount

Check the Quantity Discount Below
  • Qty 2 = 2% discount
  • Qty 3 = 4% discount
  • Qty 4 = 6% discount
  • Qty 5 = 8% discount
  • Qty more than 6 = 10% discount
TB-500 (Thymosin Beta-4) 2mg has to reconstituted with Bacteriostatic water (BAC).

You can purchase BAC water here:
BAC 10ml 
BAC 20ml 

Click here to buy 10vials (1kit) at a discounted price of $124!

The total amount of active ingredient: 2mg (1vial)

Availability: In stock

Top Color: White/Red

Shelf Life: 36 months

USA: $11.95 (3-5 business days)
International : $49.95 (7-14 business days)
If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.
Minimum Order: 1vial

TB-500 research

Thymosin Beta 4, or TB-500, is a synthetic version of a naturally occurring 43-amino acid peptide present in nearly all human and animal cells studied.

A recent report (2010) in the Annals of the New York Academy of Sciences bolstered TB500’s potential for cardiovascular muscle fix following injury, eg, after myocardial localized necrosis (coronary episode). Perceiving the restrictions of undeveloped cell treatment for this application, TB500 was found to restrain myocardial cell passing, animate vein development, and enact cardiovascular procedures that energized the heart to heal following injury. The investigation showed that TB500 may be the first agent which can actively recover injured cardiac muscle following a heart attack. This is further supported by earlier mice considers in 2004 demonstrating cardiomyocyte relocation, endurance, and fix of myocardial harm.

Filamentous actin (F-actin, or actin) structures polymers that thicken sputum, unfavorably influencing cystic fibrosis patients. TB500 was considered in a population of CF patients, demonstrating a portion and time-subordinate diminishing in cohesivity of sputum after the organization of TB500 when joined with dornase alfa. The blend treatment indicated a 71% improvement in mucociliary transport of bodily fluid and a 44% improvement in cough transport of bodily fluid.

TB500 is known to stimulate myoblasts and myocytes (muscle producing cells). Mitochondrial RNA levels of TB500 have been seemed to extend following muscle injury, helping with recuperating muscle strands and address disturbance in the hurt territory. The information support muscle injury causing expanded local creation of TB500, advancing movement of approaching myoblasts to quicken skeletal muscle recovery.

TB-500 (Thymosin Beta-4) 2mg

Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser
Molecular formula: C212H350N56O78S
Molar Mass: 4963.4408
CAS number: 77591-33-4
PubChem: CID 16132341
Synonyms: Thymosin Beta 4

Scientific Studies with TB500
A study completed in 2009 utilizing .01% TB500 w/w eye drops showed the sped up of healing following eye medical procedure in diabetics. This population was specifically investigated due to well-known healing complications in diabetics, and their predilection for eye issues, specifically diabetic retinopathy. The study showed no serious side effects in any patient, although headache, dizziness, and insomnia occurred more in the study group than the control. Of specific interest, human diabetic retinopathic corneas express substantially less endogenous TB500 than a normal cornea, suggesting an inherent deficiency in the ability for diabetics to heal following an eye injury or surgery. [5] Similarly, chronic dry-eye patients were treated with TB500 eye drops, and all in the study had an improvement in symptoms, with rare and minimal complications.

TB500 was concentrated in the setting of constant hepatitis B joined with nonalcoholic fatty liver disease (NAFLD). While TB500 had no connection with HepB Virus levels nor liver capacity tests (AST, ALT, TG), there was a negative relationship with aggravation and fibrosis scores – implying that the lower the degree of TB500, the more terrible the inflammation and fibrosis. This gave starter information that TB500 might be advantageous in the setting of certain liver ailments.

A human voluntary safety and tolerance study was performed in 2010 and showed that intravenous (IV) doses from 42mg up to 1260mg daily for 14 days had no treatment-related adverse effects and no evidence of dose-related toxicity.

Rhinovirus (a common cold virus) was introduced to healthy volunteers, and blood tests were taken during a five-day period. This demonstrated serum cortisol rose alongside thymosin alpha 1 and TB500 on the fifth day following the purposeful presentation. Simultaneously, t-lymphocytes (CD3+), cytotoxic/suppressor (CD8+), and natural killer (CD16+) cells all rose. This suggests a cooperative effect among systemic and cellular immune response related to thymosin and respiratory virus exposure.

Kidney disease frequently incorporates irritation, fibrosis, and inconveniences from diabetes. TB500 has been examined in mice with and without kidney illness; in sound mice, levels of TB500 didn’t influence solid kidney tissue, however in those with known kidney illness, low degrees of TB500 related to worsening sickness. That is, low degrees of characteristic TB500 quickened kidney illness. The investigation proposed that endogenous TB500 levels capacity to ensure the kidney and moderate disease progression.

TB500 has been studied specifically in the healing of skin and wounds, showing an acceleration in healing of the skin in burns, diabetic ulcers, elderly subjects, pressure ulcers, stasis ulcers, and epidermolysis wounds, in both animal and human subjects. The study shows improvement in angiogenesis (blood vessel formation), anti-inflammatory activity, and to increase platelet aggregation at wound sites.

A meta-analysis (the study of studies) conducted in 2015 showed the broad applicability of TB500 in various disease processes, including improvement of tissue regeneration, repair of the heart after a heart attack, healing of the brain following stroke, trauma and neurological diseases. Further, it showed clinical improvement in kidney and liver diseases, and repair of the spinal cord, bone and ligament injuries, as well as reducing consequences of aging and viral infection.

TB500 treated mice were found to have generously improved quality in mended breaks contrasted with untreated mice. Treated mice showed a 41% increase in peak force to failure, and healed fractures were 25% stiffer than untreated mice. 21-day post-fracture imaging showed improvement of up to 26% better than untreated subjects. They also showed a 23% smaller callus and a 31% increase in trabecular bone area/total callus area. Overall TB500 demonstrated substantially faster healing, with better-heeled injury sites when compared to placebo subjects.

Spinal cord injury has been studied in rats, with potential applicability to human subjects. In a 2014 study, TB500 was administered to rats 30 minutes, 3 days, or 5 days after mild compression-induced spinal cord injury in rats. Locomotor and behavioral assessments were all markedly improved with the TB500 treated group. Inflammatory cytokines were reduced, the size of scars was markedly reduced, and levels of myelin proteins were 57.8% above the control group. The study proposed that, with the known wellbeing of TB500, that it ought to be considered for the treatment of spinal cord injury in people.

While no animal model perfectly mimics humans for head injury research, rats are considered a close second due to our understanding of their behaviors. TB500 has been considered in traumatic brain injury (TBI) and has been shown to especially improve work after TBI. TB500 exerts both neuroprotective and neurorestorative effects on rats, including a proliferation of blood flow, new brain cells, and new connections between brain cells.

Multiple sclerosis has also been shown, in rat models, to benefit from the administration of TB500. Zhang et al, in their 2016 study, showed that the administration of TB500 significantly increased the number of newly generated oligodendrocytes and reduced axonal damage in the mice compared with the control group. Significantly, the recently created oligodendrocytes remyelinated axons, and this associated with practical improvement.

Steps for Mixing TB-500:

  1. Take the lids off both your bacteriostatic water and TB-500 containers.
  2. Rub the alcohol swab along the rubber stopper on the TB-500 container, and the top of the bacteriostatic water vial and allow each to air dry.
  3. Fill the insulin syringe with bacteriostatic water and slowly and carefully inject the syringe of water into the bottle of TB-500 – being careful to spray the water onto the sides of the container rather than directly into the powder. If you do this three times, you will nearly fill the bottle of TB-500.
  4. Your TB-500 is now reconstituted. Keep it in the refrigerator or freezer to preserve it until you’re ready to use it.

Do not let your mixed TB-500 sit at room temperature or in the light or it will go bad. To ensure the highest quality, it needs to be kept out of direct light and refrigerated or frozen temperatures.

When drawing TB-500 into syringes for injections, flip around the jug gradually and bring the fluid into the syringe easily and gradually. When injecting, do as such with a smooth, slow movement also. Peptides are delicate and an excessive amount of blending and shaking of the holder can harm or diminish the viability of your item.

All of our items are lab tried and the outcomes are occasionally distributed on the site.

TB-500 MS

TB-500 COA


1 – Ann N Y Acad Sci. 2010 Apr;1194:87-96. Thymosin beta4 and cardiac repair.

Shrivastava S1, Srivastava D, Olson EN, DiMaio JM, Bock-Marquette I.

2 – Nature. 2004 Nov 25;432(7016):466-72. Thymosin beta4 initiates integrin-connected kinase and promotes heart cell movement, endurance, and cardiovascular fix. Bock-Marquette I1, Saxena A, White MD, Dimaio JM, Srivastava D.

3 – Chest. 2006 Nov;130(5):1433-40. Thymosin beta4 sequesters actin in cystic fibrosis sputum and decrease sputum cohesivity in vitro. Rubin BK1, Kater AP, Goldstein AL.

4 – J Biochem. 2011 Jan;149(1):43-8. doi: 10.1093/jb/mvq115. Epub 2010 Sep 29.

Muscle injury-instigated thymosin β4 goes about as a chemoattractant for myoblasts.

Tokura Y1, Nakayama Y, Fukada S, Nara N, Yamamoto H, Matsuda R, Hara T.

5 – https://clinicaltrials.gov/show/NCT00598871

6 – Ann N Y Acad Sci. 2010 Apr;1194:199-206. doi: 10.1111/j.1749-6632.2010.05471.x.

Medication of chronic nonhealing neurotrophic corneal epithelial imperfections with thymosin beta4. Dunn SP1, Heidemann DG, Chow CY, Crockford D, Turjman N, Angel J, Allan CB, Sosne G.

7 – Medicine (Baltimore).2016 Dec;95(52):e5763. doi: 10.1097/MD.0000000000005763.

The expression of thymosin β4 in constant hepatitis B consolidated nonalcoholic greasy liver sickness. Liang J1, Cai W, Han T, Jing L, Ma Z, Gao Y.

8 – Ann N Y Acad Sci. 2010 Apr;1194:223-9. doi: 10.1111/j.1749-6632.2010.05474.x.

A randomized, fake treatment controlled, single and various portion investigation of intravenous thymosin beta4 in sound volunteers. Ruff D1, Crockford D, Girardi G, Zhang Y.

9 – Lymphokine Res. 1989 Winter;8(4):383-91. Modulation thymosin alpha 1 and thymosin beta 4 levels and fringe blood mononuclear cell subsets during exploratory rhinovirus colds. Hsia J1, Sztein MB, Naylor PH, Simon GL, Goldstein AL, Hayden FG.

10 – Kidney Int. 2016 Nov;90(5):1056-1070. doi: 10.1016/j.kint.2016.06.032. Epub 2016 Aug 26. Loss of endogenous thymosin β4 accelerates the glomerular disease.

Vasilopoulou E1, Kolatsi-Joannou M1, Lindenmeyer MT2, White KE3, Robson MG4, Cohen CD2, Sebire NJ1, Riley PR5, Winyard PJ1, Long DA6.

11 – Vitam Horm. 2016;102:251-75. doi: 10.1016/bs.vh.2016.04.005. Epub 2016 May 24.

Thymosin β4 Promotes Dermal Healing. Kleinman HK1, Sosne G2.

12 – Expert Opin Biol Ther. 2015;15 Suppl 1:S139-45.doi:10.1517/14712598.2015. 1011617. Epub 2015 Jun 22. Advances in the fundamental and clinical uses of thymosin β4. Goldstein AL1, Kleinman HK.

13 – J Orthop Res. 2014 Oct;32(10):1277-82. doi: 10.1002/jor.22686. Epub 2014 Jul 8.

Thymosin β4 administration enhances fracture healing in mice. Brady RD1, Grills BL, Schuijers JA, Ward AR, Tonkin BA, Walsh NC, McDonald SJ.

14 – Neuropharmacology. 2014 Oct;85:408-16. doi: 10.1016/j.neuropharm.2014.06.004. Epub 2014 Jun 14. Useful impacts of thymosin β4 on spinal rope injury in the rodent.

Cheng P1, Kuang F1, Zhang H1, Ju G2, Wang J3.

15 – Ann N Y Acad Sci. 2012 Oct;1270:51-8. doi: 10.1111/j.1749-6632.2012.06683.x.

Neuroprotective and neurorestorative impacts of thymosin β4 treatment following trial horrible cerebrum injury.

Xiong Y1, Mahmood A, Meng Y, Zhang Y, Zhang ZG, Morris DC, Chopp M.

16 – Neurobiol Dis. 2016 Apr;88:85-95. doi: 10.1016/j.nbd.2016.01.010. Epub 2016 Jan 12. Thymosin beta4 advances oligodendrogenesis in the demyelinating focal sensory system. Zhang J1, Zhang ZG2, Li Y2, Lu M3, Zhang Y2, Elias SB2, Chopp M4.

Also known as: Fx peptide, thymosin .beta.-4, thymosin beta(4), thymosin beta-4, thymosin beta4, Tyb-4

Peptides are stable at room temperature and can be kept in their initial packaging for several days to weeks. Otherwise, peptides can be stored at 4 °C or BELOW. Peptides should be protected from intense light.

Submit your review


There are no reviews yet.

Select your currency
USD United States (US) dollar
EUR Euro

TB-500 (Thymosin Beta-4) 2mg (price is per vial)

$33.92 If paid in BTC $27.13

Add to Cart